Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in efficacy. In the absence of head-to-head randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Joe Q., Yuile, Alexander, Itchins, Malinda, Kong, Benjamin Y., Li, Bob T., Pavlakis, Nick, Chan, David L., Clarke, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376908/
https://www.ncbi.nlm.nih.gov/pubmed/37509467
http://dx.doi.org/10.3390/biomedicines11071827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376908/
https://www.ncbi.nlm.nih.gov/pubmed/37509467
http://dx.doi.org/10.3390/biomedicines11071827

Ejemplares similares